Ocrelizumab clinical trials
Also written Ocrevus and RO4964913.
How each study uses ocrelizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ocrelizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Mar 2017 · OCREVUS · BLA 761053 (FDA, Drugs@FDA)
- European Union
- 8 Jan 2018 · Ocrevus · EMEA/H/C/004043 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
56 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2011 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 41 · Other 15
Hoffmann-La Roche (23) · Genentech, Inc. (13) · University of California, San Francisco (2) · Johns Hopkins University (2) · Sandoz (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · R-Pharm (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Immunologic Factors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 7 phase 3 studies under way
Ocrelizumab is the comparator. A study of two new drugs counts under both.
- 2Rituximab · Rigshospitalet, Denmark, Haukeland University Hospital
- 1Fenebrutinib · Hoffmann-La Roche
- 1Cyclophosphamide · Haukeland University Hospital · next primary completion Nov 2026
- 1Antilymphocyte Serum · Haukeland University Hospital · next primary completion Nov 2026
- 1Remibrutinib · Novartis Pharmaceuticals · next primary completion Jul 2029
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test ocrelizumab, phase 3 first.
- Nov 2026Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisPhase 3 · Sandoz
- Feb 2027A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisPhase 3 · Celltrion
- Dec 2026Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis OnsetPhase 4 · University of California, San Francisco
- Feb 2027B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisPhase 4 · Amsterdam UMC, location VUmc
- Jun 2027Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisPhase 4 · University of California, San Francisco
Studies
Open first, then newest update. How each study uses ocrelizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 56
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingPhase 4Genentech, Inc.NCT07609719Written as OCR SC
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruitingPhase 3Hoffmann-La RocheNCT06675955Written as Ocrelizumab
- Ocrelizumab for Psychosis by AutoimmunityRecruitingPhase 1/2The Methodist Hospital Research InstituteNCT03971487Written as Ocrelizumab infusion
- Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisEnrolling by invitationPhase 4University of California, San FranciscoNCT06495593Written as Ocrelizumab
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRecruitingPhase 3CelltrionNCT05906992Written as CT-P53
- Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT03691077Written as Ocrelizumab
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisActive, not recruitingPhase 3SandozNCT06847724Written as CYB704
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04544436Written as Ocrelizumab
- A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive, not recruitingPhase 2Hoffmann-La RocheNCT04075266Written as Ocrelizumab
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT05269004Written as Ocrelizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruitingPhase 4Hoffmann-La RocheNCT07483450Written as Ocrelizumab
- This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)CompletedPhase 3Hoffmann-La RocheNCT03599245Written as Ocrelizumab
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT05285891Written as Ocrelizumab
- Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority TrialActive, not recruitingPhase 3Fondation Ophtalmologique Adolphe de RothschildNCT05999604Written as Ocrelizumab Injection [Ocrevus]
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisCompletedPhase 3Hoffmann-La RocheNCT05232825Written as Ocrelizumab IV
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04548999Written as Ocrelizumab
- A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT03523858Written as Ocrelizumab
- A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT05123703Written as Ocrelizumab
- A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsActive, not recruitingPhase 1R-PharmNCT07597668Written as RPH-035
- Effects of Ocrevus in Relapsing Multiple SclerosisActive, not recruitingPhase 4Georgia State UniversityNCT04387734Written as Ocrelizumab
See all 56 studies that test ocrelizumab →
Given beside what is tested · 4 — ocrelizumab is usual care or a partner of the new treatment
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)RecruitingPhase 2Hoffmann-La RocheNCT07282574Written as Ocrelizumab
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Active, not recruitingPhase 2Hoffmann-La RocheNCT07074886Written as Ocrelizumab Test Formulation
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Active, not recruitingPhase 3AmgenNCT06700343Written as Ocrelizumab (US)
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisSuspendedPhase 1Indapta Therapeutics, INC.NCT06677710Written as Ocrelizumab
As the comparator · 10 — what is tested is compared with ocrelizumab
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingPhase 3Novartis PharmaceuticalsNCT06846281Written as Ocrelizumab
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingPhase 4Johns Hopkins UniversityNCT07389590Written as Ocrelizumab
- A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisRecruitingPhase 3BiocadNCT07321093Written as Ocrelizumab
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Active, not recruitingPhase 2Hoffmann-La RocheNCT07074886Written as Ocrelizumab Test Formulation
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Active, not recruitingPhase 3AmgenNCT06700343Written as Ocrelizumab (US)
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT04544449Written as Ocrelizumab
- Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisActive, not recruitingPhase 3Rigshospitalet, DenmarkNCT04688788Written as Ocrelizumab
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseActive, not recruitingPhase 3Haukeland University HospitalNCT04578639Written as Ocrelizumab
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingPhase 3Haukeland University HospitalNCT03477500Written as Ocrelizumab
- Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialTerminatedPhase 2Universitätsklinikum Hamburg-EppendorfNCT04971005Written as Ocrelizumab
Codes
What other systems call ocrelizumab · ClinicalTrials.gg INT005359
- MeSH (NLM) C533411ocrelizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A10SJL62JYOCRELIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1876366Confirmed FDA, Wikidata
- Wikidata Q2013780ocrelizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66250OcrelizumabOne source FDA
- DrugBank DB11988One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533411 | ocrelizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A10SJL62JY | OCRELIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1876366 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2013780 | ocrelizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66250 | Ocrelizumab | One source FDA |
| DrugBank | DB11988 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.